At a glance
ClinicalIndex Comparison RecordPhase 2Active· 265 enrolled
Drug / intervention
AK112 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
In Brief
A Phase 2 clinical trial evaluating AK112, Pemetrexed, and 3 other interventions for NSCLC. Active but no longer recruiting, targeting 265 participants across 1 site.
Detailed Summary
This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC
CountriesChina
Collaborators--
Timeline
Phase 2Active
2021202220232024202520262027
Enrollment StartFeb 2021
First PostedFeb 2021
Primary CompletionJul 2026
TodayJul 2026
Study CompletionDec 2026
First PostedFeb 3, 2021
Enrollment StartFeb 1, 2021
Primary CompletionJul 1, 2026
Study CompletionDec 1, 2026
TodayJul 1, 2026
Enrollment to primary: 5.4 yearsPosted 5.4 years ago
Interventions
AK112drug
IV infusion
Pemetrexeddrug
IV infusion
Paclitaxeldrug
IV infusion
Carboplatindrug
IV infusion
Docetaxeldrug
IV infusion